Dianthus Therapeutics Stock Today
| DNTH Stock | 20.44 0.15 0.73% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Dianthus Therapeutics is trading at 20.44 as of the 21st of March 2025. This is a 0.73% down since the beginning of the trading day. The stock's open price was 20.59. Dianthus Therapeutics has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Dianthus Stock Highlights
| CEO and Presidentident | Marino MBA |
| Thematic Idea | Pharmaceutical Products (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Dianthus Therapeutics (DNTH) is traded on NASDAQ Exchange in USA. It is located in 7 Times Square, New York, NY, United States, 10036 and employs 78 people. Dianthus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 661.46 M. Dianthus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 32.13 M outstanding shares of which 5.31 M shares are currently shorted by private and institutional investors with about 25.81 trading days to cover.
Dianthus Therapeutics generates negative cash flow from operations
Check Dianthus Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Dianthus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dianthus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dianthus Therapeutics. Please pay attention to any change in the institutional holdings of Dianthus Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Dianthus Ownership Details
Dianthus Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Dianthus Therapeutics market risk premium is the additional return an investor will receive from holding Dianthus Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | 0.2832 | |||
| Treynor Ratio | 0.4776 |
Dianthus Stock Against Markets
Dianthus Therapeutics Corporate Management
| Jennifer Ruff | VP Affairs | Profile | |
| Edward Carr | Chief Officer | Profile | |
| Kristina Maximenko | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Adam Esq | General Counsel | Profile | |
| Judson Taylor | Senior Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.